Showing 5451-5460 of 5909 results for "".
- Doctor Alexa Will See You Now: Is Amazon Primed To Come To Your Rescue?https://modernod.com/news/doctor-alexa-will-see-you-now-is-amazon-primed-to-come-to-your-rescue/2476782/Now that it’s upending the way you play music, cook, shop, hear the news and check the weather, the friendly voice emanating from your Amazon Alexa-enabled smart speaker is poised to wriggle its way into all things health care. Amazon has big ambitions for its devices, according to a
- Bascom Palmer Eye Institute Ranked Nation’s No. 1 in Ophthalmologyhttps://modernod.com/news/bascom-palmer-eye-institute-ranked-nations-no-1-in-ophthalmology/2476783/U.S News & World Report has once again ranked Bascom Palmer Eye Institute of the University of Miami Health System as the nation’s best in ophthalmology. Recognized as a global leader in vision research, medical education, and patient care, this year marks the 18th time that Bascom P
- Now Optics Launches New Advertising Campaign ‘The Perfect Fit’https://modernod.com/news/now-optics-launches-new-advertising-campaign-the-perfect-fit/2476780/Now Optics, which provides eyewear under the retail brands Stanton Optical and My Eyelab, has announced a new advertising campaign, ‘The Perfect Fit.’ Developed in conjunction with its agency, Barkley, ‘The Perfect Fit’ highlights walk-in eye exam appointments, eyeglasses and eyewear assor
- Alkahest Phase 2a Study AKST4290-202 in Refractory Wet AMD Meets Primary and Secondary Endpointshttps://modernod.com/news/alkahest-phase-2a-study-akst4290-202-in-refractory-wet-amd-meets-primary-and-secondary-endpoints/2476778/Alkahest announced that its phase 2a trial of AKST4290, an orally-administered small molecule CCR3 inhibitor, met the primary endpoint of achieving an increase in best corrected visual acuity (BCVA) in patients with refractory wet or neovascular age-related macular degeneration (nAMD). AKST4290 w
- Okayama University Research: Prosthetics for Retinal Stimulationhttps://modernod.com/news/okayama-university-research-prosthetics-for-retinal-stimulation/2476774/In a study recently published in Advanced Biomedical Engineering, researchers at Okayama University in Japan report a thin photoelectric film which can stimulate degenerated retinal tissues of the eye. Using electric signals to stimulate tissues is the basis of several medical devic
- Kodiak Sciences Announces Positive Interim Data from Phase 1b Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Retinal Diseaseshttps://modernod.com/news/kodiak-sciences-announces-positive-interim-data-from-phase-1b-study-of-ksi-301-a-novel-anti-vegf-antibody-biopolymer-conjugate-for-treatment-of-retinal-diseases/2476775/Kodiak Sciences announced positive interim results from the ongoing phase 1b study of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate in patients with anti-VEGF treatment-naïve wet age-related macular degeneration (AMD), diabetic mac
- Aura Biosciences to Present Long-Term Clinical Data for AU-011 at ASRShttps://modernod.com/news/aura-biosciences-to-present-long-term-clinical-data-for-au-011-at-asrs/2476767/Aura Biosciences announced that 2-year clinical data from its ongoing phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the company’s lead product candidate for the treatment of primary choroidal melanoma, will be highlighted in an oral presentation at the Am
- MicroSurgical Technology Releases MST 19-Gauge Ahmed Micro Stent Cutterhttps://modernod.com/news/microsurgical-technology-releases-mst-19-gauge-ahmed-micro-stent-cutter/2476768/To address challenging microstent revision surgery, MicroSurgical Technology (MST), in collaboration with glaucoma and cataract surgeon Ike Ahmed, MD, has developed the MST 19-gauge Ahmed Micro Stent Cutter. Bringing precision and control, the new instrument enables an efficient and minimally inv
- Omeros’ Omidria Receives Product-Specific J-Code from CMShttps://modernod.com/news/omeros-omidria-receives-product-specific-j-code-from-cms/2476766/Omeros announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary decision to assign a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3%. Omidria is
- Allegro Ophthalmics to Present Results of Its Phase 2 Risuteganib Intermediate Dry AMD Study at ASRShttps://modernod.com/news/allegro-ophthalmics-to-present-results-of-its-phase-2-risuteganib-intermediate-dry-amd-study-at-asrs/2476765/Allegro Ophthalmics announced that the results of its US phase 2 study evaluating risuteganib (Luminate) for the treatment of intermediate dry age-related macular degeneration (AMD) will be presented during the Americ